RT Journal Article
SR Electronic
T1 Limited impact of Delta variant’s mutations in the effectiveness of neutralization conferred by natural infection or COVID-19 vaccines in a Latino population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.25.21265422
DO 10.1101/2021.10.25.21265422
A1 Sariol, Carlos A.
A1 Serrano-Collazo, Crisanta
A1 Ortiz, Edwin J.
A1 Pantoja, Petraleigh
A1 Cruz, Lorna
A1 Arana, Teresa
A1 Atehortua, Dianne
A1 Pabon-Carrero, Christina
A1 Espino, Ana M.
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.10.25.21265422.abstract
AB The SARS-CoV-2 pandemic has impacted public health systems all over the world. The Delta variant seems to possess enhanced transmissibility, but no clear evidence suggests it has increased virulence. Our data shows that pre-exposed individuals had similar neutralizing activity against the authentic COVID-19 strain and the Delta and Epsilon variants. After one vaccine dose, the neutralization capacity expands to all tested variants. Healthy vaccinated individuals showed a limited breadth of neutralization. One vaccine dose induced similar neutralizing antibodies against the Delta compared to the authentic strain. However, even after two doses, this capacity only expanded to the Epsilon variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Puerto Rico Science, Technology and Research Trust supported research reported in this work under agreement number 2020-00272 to AME and CAS. Also, the University of Puerto Rico contributed with the UPR-COVID-19 Grant to CAS and AME. This work was also supported by 1U01CA260541-01 to CAS (NCI/NIAID).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples used in this study were obtained from adult volunteers (>21 years old) participating in the IRB approved clinical protocol Molecular Basis and Epidemiology of Viral infections circulating in Puerto Rico, Pro0004333. Protocol was submitted to, and ethical approval was given by, Advarra IRB on April 21, 2020. Also this protocol was approved by the IRB at the Medical Sciences Campus, University of Puerto Rico.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors